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SUMMARY 
The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma is a key event in breast 
tumor progression that is poorly understood. Comparative molecular analysis of tumor epithelial 
cells from in situ and invasive tumors has failed to identify consistent tumor stage-specific 
differences. However, the myoepithelial cell layer, present only in DCIS, is a key distinguishing and 
diagnostic feature. To determine the contribution of non-epithelial cells to tumor progression, we 
analyzed the role of myoepithelial cells and fibroblasts in the progression of in situ carcinomas 
using a xenograft model of human DCIS. Progression to invasion was promoted by fibroblasts, but 
inhibited by normal myoepithelial cells. The invasive tumor cells from these progressed lesions 
formed DCIS rather than invasive cancers when re-injected into naïve mice. Molecular profiles of 
myoepithelial and epithelial cells isolated from primary normal and cancerous human breast tissue 
samples corroborated findings obtained in the xenograft model. These results provide the proof of 
principle that breast tumor progression could occur in the absence of additional genetic alterations 
and that tumor growth and progression could be controlled by replacement of normal 
myoepithelial inhibitory signals. 
 
SIGNIFICANCE 
There has been a dramatic improvement in our ability to detect DCIS, but our understanding of the 
factors involved in its progression is poorly defined. Our data suggest that a key event of tumor 
progression is the disappearance of the normal myoepithelial cell layer due to defective 
myoepithelial cell differentiation provoked by microenvironmental signals. Thus, myoepithelial 
cells could be considered gatekeepers of the in situ to invasive carcinoma transition and 
understanding the pathways that regulate their differentiation may open new venues for cancer 
therapy and prevention. 
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INTRODUCTION 
The natural history of most breast cancers involves progression through clinical and pathologic stages 
starting with ductal hyperplasia, progressing into in situ and invasive carcinomas, and culminating in 
metastatic disease (Allred et al., 2001; Burstein et al., 2004). DCIS is thought to be one of the precursors 
of invasive ductal carcinoma based on molecular, epidemiological, and pathological studies (Burstein et 
al., 2004; Simpson et al., 2005). Whereas there has been a dramatic improvement in our ability to detect 
DCIS, our understanding of the factors involved in its progression is far behind. Comprehensive gene 
expression and genetic studies comparing the profiles of DCIS and invasive ductal carcinomas have failed 
to identify in situ and invasive tumor-specific signatures (Chin et al., 2004; Ma et al., 2003; Porter et al., 
2003; Porter et al., 2001; Yao et al., 2006). However, these studies have focused mainly on the tumor 
epithelial cells and the potential involvement of other epithelial and myoepithelial cells, and the stroma in 
tumor progression has not been explored in sufficient depth.  
Epithelial-mesenchymal interactions are known to be important for the normal development of the 
mammary gland and for breast tumorigenesis (Howlett and Bissell, 1993). In vivo and in vitro studies 
have demonstrated that cells composing the microenvironment (myoepithelial and endothelial cells, 
fibroblasts, myofibroblasts, leukocytes, and other cell types) and the ECM molecules modulate tissue-
specificity of the normal breast as well as the growth, survival, polarity, and invasive behavior of breast 
cancer cells (Bissell and Radisky, 2001; Elenbaas and Weinberg, 2001). In the normal mammary gland a 
layer of myoepithelial cells that produce, and are in contact with, the basement membrane surrounds 
luminal epithelial cells which in turn line the ducts and the alveoli. In addition to playing a role in 
expelling milk from the ducts during lactation due to their contractile function, myoepithelial cells are 
increasingly recognized as important regulators of normal mammary gland development and function due 
to their effect on luminal epithelial cell polarity, branching, and differentiation (Clarke et al., 2005; 
Gudjonsson et al., 2005; Gudjonsson et al., 2002a; Jolicoeur, 2005). Myoepithelial cells have also been 
labeled “natural tumor suppressors” due to their negative effects on tumor cells growth, invasion, and 
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angiogenesis achieved via secretion of protease inhibitors and downregulation of MMP (matrix 
metalloprotease) levels (Barsky and Karlin, 2005; Gudjonsson et al., 2005; Jones et al., 2003; Polyak and 
Hu, 2005). These conclusions have been largely based on in vitro co-culture assays; the role of 
myoepithelial cells in tumorigenesis in vivo is still poorly defined. The tumor-suppressive function of 
myoepithelial cells appear to get lost during the in situ to invasive carcinoma transition when both the 
organized myoepithelial cell layer and the basement membrane progressively disappear. The diagnostic 
criterion that distinguishes invasive from in situ carcinomas is the disappearance of the myoepithelial cell 
layer as an organized entity (Lerwill, 2004). 
To explore the potential involvement of cells composing the microenvironment in tumor progression, we 
previously analyzed the gene expression and DNA methylation profiles of different cell types purified 
from normal breast tissue, DCIS, and invasive carcinomas and observed dramatic changes in all cells 
during tumor progression (Allinen et al., 2004; Hu et al., 2005). Importantly, myoepithelial cells 
associated with DCIS were not phenotypically normal; they had lost some of their differentiation markers 
and had up-regulated genes promoting angiogenesis and invasion (Allinen et al., 2004). While the 
physiological relevance of these molecular changes was unknown, based on our data we hypothesized that 
abnormal DCIS-associated myoepithelial cells, together with various stromal cells, degrade the basement 
membrane resulting in the progression of in situ carcinomas to invasive tumors. Testing this hypothesis 
requires an experimental model of DCIS that faithfully reproduces the human disease, since analysis of 
human tissue samples only allows correlative studies. The MCF10A1 human breast cell line series is one 
of the few human models of breast tumor progression (Lewis et al., 1999; Miller, 2000; Miller et al., 
1993; Tait et al., 1996), although it is likely to reflect only a subset of breast tumors with basal-like 
features. A derivative of MCF10A1 cells is the MCF10ADCIS.com cell line (subsequently referred to as 
MCFDCIS) (Miller, 2000; Miller et al., 2000), which reproducibly forms comedo DCIS-like lesions that 
spontaneously progress to invasive tumors. This MCFDCIS xenograft model highly resembles human 
disease with respect to histopathology and natural history. Furthermore, here we show hat the gene 
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expression profiles of epithelial and myoepithelial cells purified from MCFDCIS xenografts are highly 
similar to that from primary human DCIS tumors. We used this model to explore the relative importance 
of myoepithelial cells and stromal fibroblasts in the in situ to invasive breast carcinoma transition. In this 
study we demonstrate that normal myoepithelial cells suppress, but fibroblasts enhance tumor growth and 
invasive progression in the absence of detectable genomic alterations in the tumor cells themselves. The 
gene expression profiles of DCIS-associated epithelial and myoepithelial cells isolated from primary 
human breast tissue samples correlated with the above findings and support the hypothesis that transition 
of in situ to invasive carcinoma is most likely regulated by loss of normal myoepithelial function leading 
to contact between tumor epithelial and stromal cells.  
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RESULTS 
Characterization of the MCFDCIS cells and their xenografts 
To explore whether the MCFDCIS provided a reasonable model for primary human DCIS, xenografts 
were analyzed for histology and molecular markers. We chose subcutaneous instead of orthotopic 
injections because tumors formed in the mammary fat pad became invasive regardless of conditions used 
presumably due to the invasion promoting effects of endogenous mouse fibroblasts (data not shown). 
Subcutaneous injections formed xenografts that were similar to human high-grade comedo DCIS. The 
duct-like structures were surrounded by basement membrane positive for laminin 5 and contained a layer 
of cells positive for myoepithelial markers (smooth muscle actin-SMA, CD10, and p63) (Figure 1A). 
Analysis of the tumors at different time points (3-8 weeks) after injection revealed a rapid progression 
from DCIS to invasive histology (Figure 1B). In DCIS, both SMA and p63 were expressed in the 
myoepithelial cell layer, whereas in invasive tumors, SMA-positive cells were stromal myofibroblasts, 
and a subset of tumor epithelial cells was p63 positive.  
We tested several other breast cancer cell lines in xenograft assays, however, in none of these cases we 
were able to obtain tumors with DCIS histology (Figure S1 and data not shown) suggesting that this 
characteristic is unique for the MCFDCIS cells among the cells tested. We reasoned that this uniqueness 
may be due to their proposed bipotential progenitor properties (Santner et al., 2001). To test whether both 
epithelial and myoepithelial cells were derived from the human MCFDCIS cells and that the 
myoepithelial cell layer disappeared as tumors become invasive, we performed immuno-FISH 
(fluorescence in situ hybridization) analysis of MCFDCIS xenografts. Samples were collected at different 
time points after injection, using fluorescently labeled human and mouse cot-1 DNA as probes for FISH, 
pan-cytokeratin antibody (panCK) for staining of epithelial cells, and antibody to SMA to identify 
myoepithelial cells. As anticipated, panCK-positive tumor epithelial cells were indeed of human origin in 
all tumors (Figure S2). Interestingly, SMA-positive myoepithelial cells forming a layer around the duct-
like structures were also of human origin (Figure 1C), confirming the bipotential progenitor property of 
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MCFDCIS cells. In contrast, SMA-positive myofibroblasts in the stroma were of mouse origin in all 
xenografts (Figure 1C). Immuno-FISH analysis also revealed the gradual disappearance of SMA-positive 
myoepithelial cells coinciding with the progression of DCIS to invasive tumors (Figure 1C). Since other 
MCF10 derivatives were also proposed to have progenitor properties (Santner et al., 2001), we tested 
these in xenograft assays as well, but they were either non-tumorigenic (MCF10AT cells) or formed 
invasive tumors (MCF10CA cells). Thus, of all the cells tested, the MCFDCIS cell line is the only human 
breast cancer cell line that forms DCIS xenografts.  
To dissect the progenitor properties of the MCFDCIS cells, we analyzed the expression of known 
stem/progenitor and differentiated luminal epithelial and myoepithelial cell markers in cultured cells and 
in xenografts. Based on immunohistochemistry, MCFDCIS cells grown in 2D culture were uniformly 
positive for panCK, CK18, ESA, CDH1, CD44, CK17, CK5/6, p63 and VIM, partially positive for MUC1 
and CK14, and negative for CD24, SMA, and CK19 (Figure 2A). FACS analysis showed that the cells 
were positive for ITGA6 and ITGB6, negative for CD10, and also confirmed the expression of ESA, 
CD44, CD24 and MUC1 (Figure S3A). In xenografts, most tumor epithelial cells were positive for 
panCK, ESA, CD44, CK17, CDH1, and VIM. In DCIS, p63 and SMA expression was limited to the 
myoepithelial cells which also showed decreased or no expression of MUC1, CD24, and CK18, while 
CK5/6 and CK14 demonstrated heterogeneous staining patterns with all cells positive in some areas and 
only the myoepithelial cells positive in other areas (Figure 2A). CK18, CD24, and MUC1 are thought to 
be specific for luminal epithelial cells (differentiated or committed progenitor), CD10 and SMA for 
myoepithelial cells, while CD44, CK17, CK5/6, p63, and VIM has been described as markers of 
basal/progenitor cells. Thus, based on our analyses in vitro cultured MCFDCIS cells have progenitor 
characteristics and in xenografts they differentiate into luminal and myoepithelial cells.  
To determine if all or only a subpopulation of MCFDCIS cells have progenitor properties, we sorted the 
cells based on MUC1 expression into positive (MUC1+) and negative (MUC1-) fractions and injected 
them into mice. MUC1 expression has been used for identification of cells with progenitor properties 
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(Gudjonsson et al., 2002b; Stingl et al., 1998; Stingl et al., 2001; Stingl et al., 2005), and this was the only 
cell surface marker we found heterogeneously expressed in MCFDCIS cells in culture. Both MUC1+ and 
MUC1- cells gave rise to DCIS tumors (Figure S3B), suggesting that both populations have bipotential 
progenitor properties. We also derived single-cell clones of MCFDCIS cells with different CK14 and 
MUC1 expression levels based on immunocytochemistry (Figure 2B) and immunoblotting (Figure 2C). 
Four of these independent clones were injected into mice and resulting xenografts were analyzed for 
histology and expression of cell type-specific markers. Tumors derived from all four clones had a DCIS 
histology and showed the same CK14, MUC1, SMA, and p63 expression patterns (Figure 2D). Thus, 
using this approaches we found that all or a significant fraction of MCFDCIS cells may have bipotential 
progenitor properties, and the expression patterns of some genes (CK14, p63, MUC1, CD24, etc.) were 
discordant in vitro and in vivo.  
 
Similarity of the MCFDCIS xenograft model to human DCIS at the molecular level 
To ensure that results obtained using this model system are relevant to human disease, it is essential to 
establish if the MCFDCIS xenografts reproduce human disease. Thus, to compare genetic alterations in 
MCF10A1-series cells and MCFDCIS-derived xenografts to those found in sporadic human DCIS, we 
performed SNP (single nucleotide polymorphism) array analyses. All samples had a copy number gain at 
chromosome 8q24, including C-MYC, and homozygous deletion of CDKN2A at chromosome 9p21 
(Figure S4A). The gain of 8q24 is a recurring genetic change observed in high-grade human DCIS tumors 
and homozygous deletion of CDKN2A has been described in a subset of breast carcinomas (Cairns et al., 
1995; Yokota et al., 1999), supporting the similarity between the MCFDCIS model and human disease. 
The 8q24 copy number gain was confirmed by FISH; probes covering the MYC gene revealed two 
hybridization signals on chromosome 8q and one on chromosome 10q (Figure S4B) in all cells.  
To define the similarity of MCFDCIS xenografts to human DCIS at the cellular lever, we purified luminal 
and myoepithelial cells using MUC1 and integrin beta 6 (ITGB6) as cell surface markers, respectively. 
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ITGB6 has recently been identified as a gene upregulated by p63 (Carroll et al., 2006); it is also induced 
by TGFβ1 (Zambruno et al., 1995) and involved in activation of latent-TGFβ1 (Munger et al., 1999). In 
MCFDCIS-derived DCIS xenografts, as well as in human DCIS, ITGB6 was specifically expressed in 
myoepithelial cells (Figure 1A), making it an ideal cell surface marker for their purification.  
The purity of the MUC1+ and ITGB6+ cells was confirmed by semi-quantitative RT-PCR analysis of cell 
type-specific markers. Myoepithelial cell markers CD10 (MME), SMA (ACTA2), and p63 (TP73L) were 
present only in ITGB6+ cells (Figure 3A), consistent with their myoepithelial phenotype. Although the 
cells were separated based on their MUC1 and ITGB6 cell surface protein levels, the expression of MUC1 
and ITGB6 mRNAs were not completely mutually exclusive in the two cell populations (Figure 3A).  
Next we analyzed the comprehensive gene expression profiles of MUC1+ and ITGB6+ cells using SAGE. 
SAGE data further supported the myoepithelial and luminal epithelial characteristics of ITGB6+ and 
MUC1+ cells, since several known markers of these cell types were almost mutually exclusively 
expressed in the respective SAGE libraries (Table 1 and Supplemental Excel Spreadsheet 1). 
Furthermore, genes statistically significantly differentially expressed between ITGB6+ and MUC1+ cells 
were also differentially expressed between groups of “MYOEP” and “EPI” cells derived from human 
breast tissue (Table 1 and Supplemental Excel Spreadsheet 1). Hierarchical cluster analysis of the 
relatedness of the various cell types also confirmed the myoepithelial and epithelial characteristics of 
ITGB6+ and MUC1+ cells, respectively (Figure 3B). Interestingly, ITGB6+ cells cluster between normal 
and DCIS associated myopithelial cells, thus, phenotypically they are not normal myoepithelial cells, 
consistent with their origin from the MCFDCIS tumorigenic cell line. 
Functional annotation of the genes differentially expressed between ITGB6+ and MUC1+ cells revealed 
statistically significant enrichment of genes involved in ECM, basement membrane, development, muscle 
development, and angiogenesis in ITGB6+ cells (Figure 3C). Both cell types showed high expression of 
genes related to ectoderm and epidermis development, while MUC1+ cells were enriched for plasma 
membrane proteins and genes regulating ion homeostasis (Figure 3C).  
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SAGE data indicated specific activation of the TGFβ1 and hedgehog (Hh) signaling pathways in ITGB6+ 
cells as well as in human DCIS myoepithelial cells (Table 1). Both of these pathways have been 
implicated in the regulation of progenitor cell function and myoepithelial differentiation. Thus, to dissect 
the possible mechanism of their cell type-specific activation, we analyzed the expression of their signaling 
components by semi-quantitative RT-PCR in MUC1+ and ITGB6+ cells. TGFΒR1 and TGFΒR2 
(receptors for TGFβ1) and PTCH1, PTCH2, and SMO (receptors for Hh ligands) were equally present in 
both cell populations whereas SMAD2, SMAD3, and GLI2 (transcription factors), IHH (a ligand for 
PTCH), and TGFβ1 transcriptional targets SMAD7 and TGFΒI, were expressed more abundantly in 
ITGB6+ cells (Figure 3A). These data suggest that specific activation of TGFβ1 targets in ITGB6+ cells 
may be due to the restricted expression of SMAD2 and SMAD3 in these cells, a finding that was 
confirmed also by immunohistochemical analysis of DCIS xenografts (data not shown). Hh signaling and 
GLI2 expression may be preferentially upregulated in ITGB6+ cells due to their high expression of IHH 
(Figure 3A) and BGN (Table 1), a proteoglycan recently implicated in Hh responses (Rubin et al., 2002). 
The TGFβ1 and Hh signaling pathways and p63 are all known to play important roles in the regulation of 
epithelial stem cell function and their differentiation (Liu et al., 2006; Liu et al., 2005; McKeon, 2004; 
Mishra et al., 2005) and the combination of all of them may be required for defining myoepithelial and 
luminal epithelial cell phenotypes.  
 
Potential mechanism underlying basement membrane degradation and progression to invasion 
The gene expression profiles of ITGB6+ and myoepithelial cells isolated from primary human normal and 
DCIS breast tissue suggested that one of their main functions is the synthesis and maintenance of the 
basement membrane (BM). Degradation of the basement membrane is a hallmark of malignancy and the 
definition of invasive progression. Despite the importance of this issue, the molecular mechanism 
underlying BM degradation is undefined. Several MMPs have been implicated to play a role in this 
process, but a recent study concluded that the MMPs that most likely to degrade BM in vivo are MMP14, 
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MMP15, and MMP16 (Hotary et al., 2006). To determine if upregulation of these three MMPs during 
breast tumor progression may explain in situ to invasive carcinoma progression, and to identify the cell 
type that may express them, we analyzed their expression in our SAGE data on various cell types isolated 
from normal breast tissue and in situ and invasive carcinomas (Allinen et al., 2004). This analysis showed 
that MMP14 was highly expressed in myoepithelial cells and myofibroblasts, and its expression 
significantly increased in DCIS-associated myoepithelial cells compared to normal ones (data not shown). 
This expression pattern was consistent with the hypothesis that MMP14 may be involved in BM 
degradation and also that its upregulation in DCIS myoepithelial cells contribute to invasive progression. 
To confirm the SAGE data, we analyzed the expression of MMP14 by real-time PCR in epithelial and 
myoepithelial cells purified from multiple independent cases of normal breast tissue, and in situ and 
invasive tumors, together with bulk tumor samples. High MMP14 expression was detected in 
myoepithelial cells, with highest levels in DCIS-associated myoepithelium (Figure 3D). The high MMP14 
levels seen in bulk invasive tumor tissue was due to its expression in myofibroblasts since tumor 
epithelial cells and myofibroblasts had low and high levels of MMP14, respectively (Figure 3D and data 
not shown). Next, we tested the expression of MMP14 in MUC1+ and ITGB6+ cells isolated from 
MCFDCIS xenografts and found that MMP14 was highly expressed in ITGB6+ cells (Figure 3E) 
correlating with their myoepithelial phenotype and strengthening the similarity between our model and 
human DCIS. The high expression of MMP14 in ITGB6+ cells in the MCFDCIS xenografts also indicates 
that these cells are more similar to DCIS-associated than normal myoepithelial cells and could also 
explain why they are not able to permanently inhibit progression to invasion.  
 
The effect of co-injected myoepithelial cells and fibroblasts on tumor growth and progression 
Following the verification that the MCFDCIS xenograft model reproduces main aspects of human DCIS 
tumors, we used this model to test the role of non-epithelial cells in tumor progression. Thus, we injected 
MCFDCIS cells into nude mice alone or together with normal spontaneously immortalized HME50 (Shay 
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et al., 1995), E6/E7-immortalized D920 494/3 (Gudjonsson et al., 2002a), or primary cultured 
myoepithelial cells, or primary cultured fibroblasts derived from normal breast tissue (PBS), invasive 
ductal carcinomas (PBTS), rheumatoid arthritis (RASF), skin, or osteoarthritis (OASF). All xenografts 
were analyzed at early (3-4 weeks) time-points after injection in order to avoid spontaneous progression 
to invasive tumors. Normal myoepithelial cells statistically significantly suppressed tumor weight; 
fibroblasts from normal breast, skin, and osteoarthritis had no measurable effect; and fibroblasts from 
breast tumors and rheumatoid arthritis increased tumor weight (Figure 4A and data not shown). 
Microscopic examination revealed dramatic differences in histology among the different co-injection 
groups. MCFDCIS cells alone or co-injected with normal myoepithelial cells formed DCIS whereas co-
injection of any fibroblasts resulted in invasive carcinomas (Figure 4B and data not shown). The DCIS 
and invasive histology was confirmed by the immunohistochemical analysis of myoepithelial markers 
(Figure 3B). Analysis of the expression of MIB1 (Ki67), a commonly used cell proliferation marker, 
revealed increased proliferation in invasive tumors (Figure 4B), correlating with their faster growth rate 
(data not shown). All of these experiments were performed at least three times with essentially the same 
results using myoepithelial cells and fibroblasts derived from multiple independent patients. The tumor 
growth-suppressing effect of normal myoepithelial cells was not specific for the MCFDCIS cell line, 
since similar results were obtained when myoepithelial cells were used with other breast cancer cell lines 
(MCF7, MDA-MB-231, MDA-MB-435, and SK-BR-3) for co-injections (data not shown).  
To determine the species of origin and localization of various cell types in the xenografts, immuno-FISH 
experiments were performed on representative tumors from each experimental group. Consistent with 
prior studies describing the lack of long-term survival of human primary (not immortalized) stromal cells 
in xenografts in immunodeficient mice (Kuperwasser et al., 2004), we were not able to detect human 
fibroblasts in the stroma in any of the tumors (Figure 4C-D). All SMA-positive myofibroblasts in the 
stroma were mouse origin, while cytokeratin positive epithelial and SMA-positive myoepithelial cells, 
present only in DCIS tumors, were human. We repeated these experiments in NOD/SCID mice, a more 
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severely immunodeficient mouse strain in which human stromal cells have been reported to survive 
longer (Kuperwasser et al., 2004), but even in these tumors, we detected only occasional human 
fibroblasts in the stroma (data not shown). Thus, despite their inability to persist long-term in 
immunodeficient mice, co-injected fibroblasts exert a long-lasting effect on tumor weight and histology. 
The lack of requirement for their long-term survival was demonstrated also by the use of lethally 
irradiated fibroblasts for co-injections, which also resulted in invasive tumors and an even more 
pronounced increase in tumor weight (data not shown). 
We also analyzed xenografts obtained from the co-injection of all three cell types: MCFDCIS tumor cells, 
normal myoepithelial cells, and fibroblasts. Interestingly, inclusion of normal myoepithelial cells was able 
to reverse the tumor growth and progression-promoting effects of all fibroblasts, since tumors derived 
from triple-injections were smaller and had DCIS histology (Figure 4E-F).  
To determine if the tumor growth and progression-promoting effects of co-injected human fibroblasts 
were due to the preferential outgrowth of a minority subpopulation of MCFDCIS cells with preexisting or 
acquired alterations leading to invasion, we isolated tumor epithelial cells from xenografts formed from 
MCFDCIS cells alone and from different co-injections, and re-injected them (without adding any non-
epithelial cells) into new (naïve) nude mice. All re-injected tumors had DCIS histology, suggesting that 
the MCFDCIS epithelial cells were similar in all tumors and that fibroblasts have to be present at the time 
of injection to exert their progression-promoting effects (Figure 4G). SNP array analysis of xenografts 
formed from MCFDCIS cells at different time points (3-8 weeks) and from the different co-injection 
groups also demonstrated that all xenografts, with the exception of two tumors, were indistinguishable 
from the parental MCFDCIS cells (Figure S4C). Thus, acquisition of additional genetic alterations is not 
necessary for progression to invasive tumors.  
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The role of COX2 in epithelial-stromal interactions and tumorigenesis  
COX2 has been implicated in early stages of breast tumorigenesis, the regulation of mammary epithelial 
cell immortalization and proliferation, and epithelial-stromal cell interactions (Crawford et al., 2004; Sato 
et al., 2004; Shim et al., 2003). To evaluate the expression of COX2 in our model system we performed 
immunohistochemical analysis of representative tumors from each experimental group. The level of 
COX2 was fairly low and heterogeneous in MCFDCIS and MCFDCIS+HME tumors, whereas co-
injection of fibroblasts led to its dramatic up-regulation in tumor epithelial cells (Figure 5A). This 
observation is consistent with studies reporting heterogeneous COX2 expression in human breast tumors 
(Leo et al., 2006) and a recent finding in pancreatic cancer where COX2 expression is markedly 
augmented in tumor cells in response to co-culture with fibroblasts, and downregulation of COX2 
decreased the invasive properties of cancer cells acquired through epithelial-mesenchymal interactions 
(Sato et al., 2004). However, in contrast to this in vitro pancreatic cancer study, we did not see 
upregulation of COX2 in the stromal cells of any of the xenografts (data not shown). The MCFDCIS cell 
alone xenografts were mostly negative for COX2 expression even at later time points (7-8 weeks) after 
injection when all the tumors were invasive (data not shown). Thus, upregulation of COX2 in tumor 
epithelial cells is not a consequence of the cell-autonomous invasive phenotype, but due to the co-injected 
human fibroblasts. 
COX2 is known to contribute to tumor cell invasion and angiogenesis (Mann et al., 2005; Singh et al., 
2005). To investigate the association between COX2 expression and markers of invasion and 
angiogenesis, we analyzed the mRNA levels of COX2 (PTGS2), MMP9, MMP13, MMP14, MMP15, 
MMP16, VEGFA, VEGFC, and CXCL12 by quantitative RT-PCR in representative tumors from each 
experimental group. Overall, co-injection of normal myoepithelial cells decreased while that of fibroblasts 
increased the expression of most angiogenesis and invasion-related genes analyzed, but the observed 
differences were not always statistically significant (Figure 5B and data not shown). Interestingly, the 
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expression of MMP14 (MT1-MMP) was consistently upregulated in all of the invasive xenografts 
consistent with its proposed role in the degradation of basement membrane (Hotary et al., 2006).  
Based on these observations we hypothesized that upregulation of COX2 in the tumor epithelial cells by 
co-injected fibroblasts may be responsible for their tumor growth and progression-promoting effects, and, 
thus, these may be abolished or decreased by inhibition of COX2 activity. To test this hypothesis, we 
analyzed the consequences of treatment with celecoxib, a COX2-specific inhibitor, on the weight and 
histology of xenografts derived from MCFDCIS cells injected alone or together with RASF inflammatory 
fibroblasts. Feeding the mice with a celecoxib-containing diet had no significant effect on the growth of 
MCFDCIS cells alone xenografts, but it completely eliminated the tumor-growth promoting effects of the 
co-injected RASF fibroblasts (Figure 5C) and partially inhibited DCIS progression to invasive tumors 
(Figure 5D). Therefore at least part of the tumor progression promoting effects of the stroma is mediated 
via COX2. Tumor suppression by celecoxib are unlikely to be due to its anti-inflammatory properties, 
since we did not detect infiltrating inflammatory cells (CD45+ cells) in any of the xenografts (data not 
shown). 
 
Dual role for the basement membrane in tumor progression  
Our gene expression data of epithelial and myoepithelial cells purified from MCFDCIS xenografts and 
human primary tissue samples suggested the preferential activation of the TGFβ1 and p63 pathways in 
myoepithelial cells (Table 1). Prior studies in keratinocytes demonstrated that TGFβ1 influences p63 
expression (Waltermann et al., 2003). Thus, we asked whether treatment with TGFβ1 influences p63 
protein levels or activity in MCFDCIS cells in which the predominant p63 isoform is ΔNp63α based on 
immunoblot and RT-PCR analyses (data not shown). MCFDCIS cells grown in 2D or in suspension 
cultures were analyzed at different time points following TGFβ1 treatment for the expression of p63 and 
for common targets of the two pathways. TGFβ1 did not effect p63 protein levels in any conditions 
analyzed, however, loss of ECM contact itself resulted in dramatic loss of p63 protein levels (Figure 6A), 
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consistent with prior studies in MCF-10A cells (Carroll et al., 2006). The basal levels of integrin β6 and 
vimentin were slightly higher in suspended cells, whereas the induction of vimentin by TGFβ1 was less 
pronounced in suspension than in attached cells (Figure 6A). Thus, whereas TGFβ1 did not influence p63 
protein levels, cell-ECM interaction appears to dramatically influence both signaling pathways, with p63 
expression and thus the basal/myoepithelial phenotype being absolutely dependent on ECM contact.  
p63 has been shown to play an essential role in the regulation of epithelial stem cell function and 
differentiation (McKeon, 2004). To determine if constitutive overexpression of p63 would influence 
luminal and myoepithelial cell differentiation and the phenotype of the DCIS xenografts, we generated 
derivatives of MCFDCIS cells overexpressing ΔNp63α or TAp63γ. Functional overexpression of ΔNp63α 
was confirmed by immunoblot analysis of its expression as well as that of its transcriptional targets 
ITGB6, laminin 5, and vimentin (Figure 6B). Both ITGB6 and laminin 5 mediate cell-ECM interactions 
and their upregulation is consistent with the recent finding that p63 regulates epithelial survival and cell 
adhesion (Carroll et al., 2006). Despite several attempts, we were unable to obtain MCFDCIS derivatives 
with constitutive TAp63γ overexpression (Figure 6B and data not shown). Similarly decreasing p63 
expression in MCFDCIS cells using shRNA resulted in cell death (data not shown). Injection of control 
and ΔNp63α-overexpressing MCFDCIS cells into mice revealed no significant difference in tumor 
growth and histology between the two experimental groups (Figure 6C and data not shown). Intriguingly, 
despite the overexpression of ΔNp63α in MCFDCIS cells prior to injection, in the resulting xenografts 
p63 was only detected in myoepithelial cells (Figure 6C), suggesting its post-transcriptional 
downregulation in luminal epithelial cells, potentially due to lack of contact with basement membrane. 
Thus, the basement membrane appears to have a dual role in the inhibition of in situ to invasive 
carcinoma transition: it serves as barrier separating epithelial and myoepithelial cells from the stroma, and 
it is also required for the differentiation and maintenance of myoepithelial cells (Figure 6D).  
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DISCUSSION 
The DCIS to invasive carcinoma transition is a clinically important, but poorly understood step of breast 
tumorigenesis (Allred et al., 2001; Burstein et al., 2004). We and others have analyzed the gene 
expression and genetic profiles of tumor epithelial cells isolated from DCIS and invasive tumors, but have 
not been able to define a tumor stage-specific molecular event (Chin et al., 2004; Ma et al., 2003; Porter et 
al., 2003; Porter et al., 2001; Yao et al., 2006). At the same time, the importance of changes in the 
microenvironment during tumor progression has been increasingly recognized (Bissell and Radisky, 
2001; Ronnov-Jessen et al., 1996; Tlsty and Hein, 2001; Weinberg and Mihich, 2006). Myoepithelial cells 
were shown to be responsible for formation of polarized breast acini in 3-dimensional cultures 
(Gudjonsson et al., 2002a), and focal disruption of basement membrane appears to coincide with the 
disappearance of myoepithelial cells and stromal changes in human DCIS with high risk of progression to 
invasive carcinoma (Man et al., 2003). Correlating with the disappearance of the myoepithelial cells 
during the in situ to invasive carcinoma transition, the gene expression and epigenetic profiles of 
myoepithelial cells associated with DCIS become distinct from those in normal breast (Allinen et al., 
2004; Hu et al., 2005). The signals that initiate these changes are unknown, although paracrine 
interactions with neoplastic epithelial and a variety of stromal cells are potential candidates. In contrast to 
normal myoepithelial cells, tumor-associated fibroblasts and myofibroblasts have been shown to promote 
tumorigenesis via enhancing angiogenesis, and proliferation, survival, invasive, and metastatic behavior 
of tumor epithelial cells (Bissell and Radisky, 2001; Ronnov-Jessen et al., 1995; Tlsty and Hein, 2001; 
Weinberg and Mihich, 2006). We therefore tested the hypothesis that myoepithelial cells and fibroblasts 
regulate the in situ to invasive carcinoma transition using a xenograft model of human DCIS based on the 
MCFDCIS cell line.  
The MCFDCIS cells form DCIS-like xenografts that progress to invasive carcinomas with time. Based on 
co-injection experiments, we demonstrated that in the absence of normal myoepithelial cells and 
regardless of their tissue of origin, fibroblasts promoted progression of DCIS to invasive tumors and 
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upregulated COX2 expression in tumor epithelial cells. Additionally, breast tumor-associated and even 
more dramatically rheumatoid arthritis synovium-associated fibroblasts, also increased tumor growth, at 
least in part due to their induction of COX2 in tumor epithelial cells, since treatment with COX2 inhibitor 
diminished this effect. Upregulation of COX2 has been implicated in breast tumor initiation and 
metastatic progression, but this is still controversial. Our analysis of COX2 expression in primary breast 
tumors and breast cancer cell lines did not reveal consistent overexpression compared to normal epithelial 
cells (Zhao et al. submitted). Similarly, a recent study did not detect significant increase in COX2 protein 
levels during tumor progression (Leo et al., 2006). Thus, deciphering the role of COX2 in breast tumor 
progression requires further studies. 
Co-injection of normal myoepithelial cells overcame the tumor progression-promoting effects of 
fibroblasts and effectively suppressed tumor weight. Most importantly, these differences in tumor growth 
and histology were not caused by permanent changes in the epithelial cells of the tumors: based on SNP 
array analysis and only with a couple of exceptions, all xenografts were genetically identical to the 
parental MCFDCIS cells. Furthermore, MCFDCIS cells retrieved from invasive tumors were still able to 
form DCIS when re-injected into naïve mice in the absence of additional fibroblasts.  
We found that the unique ability of the MCFDCIS cells to form DCIS is due to their bipotential 
progenitor property that allows them to differentiate into luminal epithelial and myoepithelial cells in 
vivo. Differentiation to the myoepithelial cell phenotype is required for DCIS histology, and this process 
is influenced by co-injected normal myoepithelial cells and fibroblasts presumably via paracrine factors 
including laminin 1 (Gudjonsson et al., 2002a). Our gene expression profiling of immortalized normal 
myoepithelial cells and fibroblasts used for co-injections identified many candidate molecules that could 
mediate these interactions in vivo (data not shown). Most likely, a combination of these factors is 
necessary to influence the differentiation of bipotential progenitors into distinct lineages.  
Based on our immunohistochemical analyses and gene expression profiling of luminal (MUC1+) and 
myoepithelial (ITGB6+) cells isolated from DCIS xenografts, we identified p63, Hh, and TGFβ1 
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signaling pathways as potential regulators of the luminal and myoepithelial cell phenotypes. Many of the 
targets of these pathways encode ECM proteins and receptors, and several of these are regulated by more 
than one signaling pathway. For example, both p63 and TGFβ1 upregulate ITGB6 expression which in 
turn can activate latent-TGFβ1, generating a positive feed-back loop. At the same time, p63 protein levels 
are regulated by cell-ECM interactions, and luminal epithelial differentiation may be initiated by 
detachment from basement membrane and subsequent downregulation of p63. Thus, the integrity of the 
basement membrane may be key to the maintenance of the basal/myoepithelial cell layer. We believe the 
proteases secreted by tumor epithelial and the other cells in the microenvironment promote tumor 
progression via destroying the basement membrane and inhibiting progenitor to myoepithelial cell 
differentiation. Previously it was shown that destruction of basement membrane by MMP3 in transgenic 
mice was accompanied with formation of aberrant stroma and eventual mammary tumors (Sternlicht et 
al., 1999; Thomasset et al., 1998). Furthermore destruction of basement membrane by MMP3 in a non-
malignant mouse mammary cell line in culture was shown to accompany acquisition of genomic 
instability (Radisky et al., 2005). Consistent with these, we found dramatic up-regulation of MMP14 in 
DCIS associated myoepithelial cells in human tissue samples and in the ITGB6+ myoepithelial cells in 
MCFDCIS xenografts. Furthermore, gene ontology analysis of genes differentially expressed between 
epithelial and myoepithelial cells isolated from primary human tissue samples as well as from MCFDCIS 
xenografts, demonstrated that myoepithelial cells play important roles in basement membrane synthesis 
and degradation. The phenotypic changes that occur in these cells in DCIS lead to progressive degradation 
of the basement membrane, which eliminates the barrier between the epithelial and stromal cell 
compartments and also results in the loss of myoepithelial cells. Human DCIS has been shown to have 
numerous genetic alterations and is almost indistinguishable from the invasive tumors (Chin et al., 2004).  
As such additional mutations are not necessary for the in situ to invasive transition; loss of the basement 
membrane, epithelial cell organization and polarity due to disappearance of myoepithelial cells, appears to 
be sufficient to pave the way for tumor progression and invasion. A simplified view of these dynamic 
 20 
cellular and signaling interactions and their effect on the DCIS to invasive carcinoma progression are 
summarized in Figure 6D. Breast tumors are very heterogeneous with several distinct molecular subtypes 
and potentially distinct tumor progression pathways. MCFDCIS cells resemble basal-like breast tumors 
that thought to originate from bipotential stem cells (Yehiely et al., 2006). Specifically, the ITGB6+ 
myoepithelial cells are derived from MCFDCIS cells, thus, they are genetically abnormal contrary to 
myoepithelial cells isolated from human non-basal DCIS (Allinen et al., 2004). Thus, our model may not 
be universally true for all breast tumors and there are possibly other pathways of progression to invasive 
breast carcinoma. 
In summary, our data suggest that the progression of in situ to invasive breast carcinoma may not be due 
to the intrinsic properties of the tumor epithelial cells acquired during tumor evolution, but determined by 
complex interactions among all the cell types that compose the tumor microenvironment. Our conclusions 
are based on a xenograft model of human DCIS and the characterization of individual cell types isolated 
from primary human breast tissue samples. Our model is also consistent with clinical and pathology data 
in human patients as well as with data from animal models of breast cancer. Thus, our results not only 
highlight the importance of the microenvironment in tumor progression, but also point to the significance 
of the myoepithelial cell layer as the gatekeeper of DCIS. Furthermore, the results suggest that therapeutic 
strategies targeting interactions of tumor epithelial cells with their surroundings may be more beneficial to 
inhibiting tumor progression than focusing on the tumor cells alone.    
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EXPERIMENTAL PROCEDURES 
Cells and tissue specimens 
MCF10A1 and its derivative cells were obtained from Dr. Fred Miller (Karmanos Cancer Institute, 
Detroit, MI). Immortalized myoepithelial cells HME50 (Shay et al., 1995) and D920 494/3 (Gudjonsson 
et al., 2002a) were generously provided by Drs. Jerry Shay (UT Southwestern, Dallas, TX) and Mina 
Bissell (Lawrence Berkeley National Laboratory, CA), respectively. RASF and OASF were generous 
gifts by Drs. Steve Goldring (Beth-Israel Deaconess Medical Center, Boston, MA) and John D. Mountz 
(University of Alabama, Birmingham, AL). Skin fibroblasts were purchased from Coriell Institute for 
Medical Research (Camden, NJ) and American Type Culture Collection (Manassas, VA). Primary 
cultured myoepithelial cells and primary breast normal or tumor stroma were purified from tissue samples 
from the Brigham and Women’s Hospital (Boston, MA) as previously described (Allinen et al., 2004). All 
human tissue was collected using protocols approved by the Institutional Review Boards; informed 
consent was obtained from each individual who provided tissues with linked clinical data. Cells were 
grown in the media recommended by the providers. MCF10A series cells were cultured in DMEM/F12 
(Invitrogen, Carlsbad, CA) supplemented with 5% horse serum, EGF, insulin, cholera toxin, and 
hydrocortisone (all from Sigma, St. Louis, MI); myoepithelial cells were maintained in MEGM 
(Cambrex, Walkersville, MD), while fibroblasts were kept in DMEM (Invitrogen, Carlsbad, CA) with 
10% iron fortified bovine calf serum (Hyclone, Logan, UT). Generation of VSV-G pseudotyped 
retroviruses expressing human ΔNp63α and TAp63γ cDNAs and retroviral infection of MCFDCIS cells 
were carried out as previously described (Carroll et al., 2006). Cells were selected and maintained in 2 
µg/ml and 1 µg/ml puromycin, respectively. 
 
Mouse xenograft experiments 
For xenograft studies 100,000 MCFDCIS cells were injected subcutaneously into 6-9 week old female 
nude mice alone or together with 2-3 fold excess of HME, RASF, PBS, or PBTS cells in 50% Matrigel 
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(BD Biosciences, Bedford, MA). Tumors were allowed to grow for 3-8 weeks. Xenografts were weighed 
and then either snap frozen on dry ice and stored at -80oC for DNA/RNA purification, formalin fixed and 
paraffin embedded, or processed for cell sorting. For celecoxib experiments, mice were fed with a control 
AIN-93G diet (Dyets, Inc., Bethlehem, PA) or an AIN-93G diet with 0.9 g/kg celecoxib (LKT 
Laboratories, St. Paul, MN) starting 7-10 days before injection and continued for the duration of the 
experiment. 
 
Immunohistochemistry, immunocytochemistry, immunoblot, and FACS analyses 
The list of antibodies used is provided in the Supplemental Table 1. Immunohistochemistry, immunoblot, 
and FACS analyses were performed as recommended by the suppliers and essentially as previously 
described (Allinen et al., 2004; Polyak et al., 1994). For immunocytochemistry, cells were fixed with 
HistoChoice Tissue Fixative (Amresco, Solon, OH), and permeablized with 0.5% Triton X-100. Cells 
were blocked and incubated with primary antibodies, followed by biotin-conjugated secondary antibodies, 
ABC kit (Vector Labs, Burlingame, CA), and DAB Peroxidase Substrate (Sigma, St. Louis, MI). 
 
FISH, immuno-FISH, and SNP array analysis 
For MYC FISH LSI C-MYC (Spectrum Orange), LSI MYC Dual Color Break Apart Probe (5’ Spectrum 
Orange, 3’ Spectrum Green), CEP8 (Spectrum Aqua and Spectrum Green), and CEP10 (Spectrum Aqua) 
probes were purchased from Vysis, Inc. (Downers Grove, IL). Cells were treated with colcemid, 
harvested, and used for metaphase chromosome spreads preparations according to standard protocols. 
Hybridization of metaphase chromosomes was performed as previously described (Ney et al., 1993). 
Slides were examined using a fluorescence microscope equipped with a CytoVysion capturing system. 
Immuno-FISH was performed following previously described procedures (Peters et al., 2005), but using 
CK and SMA antibodies and Cot1 DNA. SNP array analysis was performed by the Dana-Farber 
 23 
Microarray Core using Affymetrix 11K XbaI SNP arrays and protocols recommended by Affymetrix 
(Santa Clara, CA) essentially as described previously (Allinen et al., 2004). 
 
Cell purification, SAGE, PCR, and statistical analyses  
Cell purification and SAGE library generation and analyses were performed as described previously 
(Allinen et al., 2004), except that MUC1 (clone DF3) and ITGB6 (clone 3G9) antibodies were used. Gene 
ontology enrichment scores for the SAGE libraries were calculated as –log(p-value) by comparing the 
significantly highly expressed genes in the two cell types analyzed to the background (all genes in the two 
libraries) with one-sided Fisher test. Details of the clustering analysis are described in the Supplemental 
Data. cDNA synthesis, and quantitative and semi-quantitative RT-PCR were carried out essentially as 
described (Allinen et al., 2004; Hu et al., 2005; Yao et al., 2006). A list of primers used for PCR analyses 
is available upon request. Xenografts weights and relative gene expression levels were analyzed using a 
two-sided exact Wilcoxon Rank Sum test stratified by experiment when the data from different 
experiments were combined. In mouse xenograft experiments when both sides of the mouse got the same 
injection and the weights of the two tumors correlated, the average of the two tumor weights was used as 
the end point. There were no corrections for multiple comparisons. 
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FIGURE LEGENDS 
Figure 1. Histologic similarity of MCFDCIS model to human DCIS. A: Comparison of MCFDCIS 
xenografts and human high-grade comedo DCIS analyzed by hematoxylin-eosin staining (H&E) to depict 
histology and immunohistochemistry for the expression of SMA, CD10, p63, ITGB6, and basement 
membrane (BM) marker laminin 5. B: Progression of the MCFDCIS xenografts. Histology of the tumors 
(H&E) and expression of SMA, p63, and ITGB6 were analyzed at the indicated time points after 
injection. C: Immuno-FISH analysis of the time course experiment demonstrates the presence of SMA-
positive human myoepithelial cells in DCIS that disappear in invasive tumors. Immunofluorescence using 
smooth muscle actin antibody (SMA-blue) identifies myoepithelial cells or myofibroblasts. Fluorescently 
labeled human (green) and mouse (red) Cot1 DNA were used as probes for FISH. Yellow arrows and 
stars indicate human myoepithelial cells and mouse myofibroblasts, respectively.  
 
Figure 2. Progenitor property of MCFDCIS cells. A: Immunohistochemical analyses of the indicated 
markers in MCFDCIS cells (in vitro) or xenografts (in vivo). B: Immunocytochemical analysis of CK14 
expression in independent single-cell clones of MCFDCIS cells. C: Immunoblot analysis of CK14 and 
MUC1 expression in independent single-cell clones of MCFDCIS cells. D: Immunohistochemical 
analyses of the indicated markers in xenografts derived from the single-cell clones. All clones gave rise to 
DCIS-like tumors, but clone 7 had a more invasive component. In vivo, the expression pattern of all 
proteins is the same in all clones regardless of their expression in vitro.  
 
Figure 3. Molecular similarity of MCFDCIS model to human DCIS. A: Semi-quantitative RT-PCR 
analysis of the expression of cell type-specific markers, and mediators of TGFβ1 and hedgehog (Hh) 
signaling in MUC1+ and ITGB6+ cells purified from DCIS xenografts. Myoepithelial markers are only 
detected in ITGB6+ cells. ITGB6+ cells also show higher levels of certain genes involved in TGFβ1 and 
Hh signaling. B: Cluster analysis of the indicated SAGE libraries to delineate similarities of MUC1+ and 
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ITGB6+ cells to human breast epithelial and myoepithelial cells, respectively. C: Gene ontology 
categories enriched in ITGB6+ myoepithelial and MUC1+ luminal epithelial cells. Scores >1.3 
corresponds to p <0.05. D: Relative expression level of MMP14 in bulk DCIS (cadmium yellow) and 
invasive ductal carcinoma (crimson), and in epithelial (red) and myoepithelial (green) cells purified from 
normal breast tissue, in situ and invasive carcinomas. E: Relative expression level of MMP14 in MUC1+ 
(red) and ITGB6+(green) cells. 
 
Figure 4. The effect of non-epithelial cells on MCFDCIS xenograft growth and histology. A: The 
effect of co-injection of different cells on tumor weight. Normal myoepithelial cells (HME) statistically 
significantly suppressed tumor weight (p=0.04), fibroblasts from normal breast (PBS) had no effect 
(P=0.61), and fibroblasts from breast tumors (PBTS) and rheumatoid arthritis synovium (RASF) 
increased tumor weight (p=0.08 and p=0.15, respectively). B: Histological and immunohistochemical 
analyses of MCFDCIS xenografts from co-injection experiments. MCFDCIS cells injected alone or co-
injected with normal myoepithelial cells form DCIS-like tumors, while co-injection of any fibroblasts 
results in invasive tumors. In DCIS-like tumors, the expression of p63 and ITGB6 is limited to a layer of 
cells with myoepithelial features, while in invasive tumors, a subset of epithelial cells are p63 and ITGB6 
positive. SMA is detected in myoepithelial cells (only in DCIS-like tumors) and in myofibroblasts. The 
number of cells positive for the MIB1 proliferation marker correlates with overall tumor size and weight. 
C: Immuno-FISH using pan-cytokeratin antibody (panCK-blue) identifies epithelial cells. The overlay 
demonstrates the human origin of cytokeratin positive epithelial cells and the mouse origin of stromal 
cells. D: Immuno-FISH using smooth muscle actin antibody (SMA-blue) identifies myoepithelial cells or 
myofibroblasts. The overlay demonstrates the human origin of SMA-positive myoepithelial cells (yellow 
arrows) in DCIS structures and the mouse origin of SMA-positive myofibroblasts (yellow stars). E-F: The 
dominant effect of normal myoepithelial cells on tumor weight (E) and histology (F). Normal 
myoepithelial cells overcome the tumor weight and progression-enhancing effects of fibroblasts, since 
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tumors resulting from the injection of MCFDCIS cells together with PBS+HME, PBTS+HME, and 
RASF+HME are significantly smaller (PBS: p=0.11, PBTS: p=0.09, and RASF: p=0.0007) and have 
DCIS histology compared to xenografts initiated from MCFDCIS cells co-injected with fibroblasts (PBS, 
PBTS, or RASF). G: The reversibility of the effect of fibroblasts on tumor phenotype. Tumors were 
removed and analyzed 22 days after injection, at which time tumors from MCFDCIS cells injected alone 
(-) or co-injected with myoepithelial cells (HME) all form DCIS, while co-injection of breast fibroblasts 
(PBS or PBTS) results in invasive tumors (Original day 22). Re-injection of cells isolated from these 
tumors resulted in DCIS-like xenografts (Reinjected day 22).  
 
Figure 5. COX2 as a mediator of epithelial-stromal cell interactions. A: Immunohistochemical 
analysis of COX2 expression in MCFDCIS xenografts. Low expression is detected in MCFDCIS cells 
injected alone (-) or co-injected with normal myoepithelial cells (HME), while co-injection of any 
fibroblasts upregulates COX2 in tumor epithelial cells. B: qPCR analysis of human-specific PTGS2 
(COX2), MMP14, VEGFA, and VEGFC gene expression in MCFDCIS xenografts. Decreased and 
increased expression of these genes is detected in MCFDCIS cells co-injected with normal myoepithelial 
cells (HME) and fibroblasts (PBS, PBTS, or RASF), respectively. C-D: The effect of a COX2 inhibitor 
(celecoxib) on the weight (C) and histology (D) of MCFDCIS xenografts derived from cells injected 
alone (-) or co-injected with RASF on control or celecoxib-containing diets. Xenografts from MCFDCIS 
cells alone (-) have DCIS histology and low COX2 expression, regardless of diet. Tumors from 
MCFDCIS cells co-injected with RASF show an invasive phenotype and high COX2 levels in the control 
diet group. Celecoxib completely abolished the tumor growth-stimulating effects of RASF (p=0.0001), 
partially inhibited the progression to invasive tumors, and decreased COX2 protein levels. No significant 
difference in cell proliferation (MIB1) is detected following celecoxib treatment.  
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Figure 6. Pathways regulating in situ to invasive carcinoma progression. A: Immunoblot analysis of 
TGFβ1-treated MCFDCIS cells in attached or suspension culture. Integrin β6, laminin 5, and vimentin are 
increased following TGFβ1 treatment regardless of ECM contact. p63 is not affected by TGFβ1, but it is 
downregulated in suspension. B: Immunoblot analysis of MCFDCIS cells infected with control (pBabe), 
ΔNp63α, and TAp63γ-overexpressing retroviruses. ΔNp63α overexpression increases integrin β6, laminin 
5 and vimentin levels. C: p63 expression in xenografts derived from vector control (pBabe) and ΔNp63α 
overexpressing MCFDCIS cells. Despite its widespread overexpression in vitro, in xenografts only the 
myoepithelial cells are positive for p63. D: Hypothetical model summarizing our results and explaining in 
situ to invasive carcinoma progression. The MCFDCIS progenitor cells can give rise to myoepithelial and 
luminal epithelial cells. Myoepithelial cells are necessary for the formation of DCIS, and their 
differentiation is negatively and positively regulated by stromal fibroblasts and normal myoepithelial 
cells, respectively, presumably through ECM remodeling. Basement membrane (BM) regulates the 
myoepithelial phenotype via its influence on p63 expression. At the same time, p63 regulates ECM 
components and contact, forming a positive feedback loop. The augmented TGFβ1 signaling in 
myoepithelial cells also modulates cell-ECM interaction. In contrast to the role of normal myoepithelial 
cells in BM synthesis and maintenance, DCIS-associated myoepithelial cells express high levels of 
MMP14, leading to gradual degradation of BM. Thus, the balance between BM deposition and 
deconstruction is the determinant of the in situ to invasive transition. 
 
 
 
Table 1. Similarity of MUC1+ and ITGB6+ cells to breast epithelial and myoepithelial cells purified from 
primary human tissue samples. Detailed description of SAGE libraries and analysis of SAGE data are 
included in the Supplemental data section. Genes were selected based on the following criteria: (1) statistically 
significant (p<0.05) difference between ITGB6+ and MUC1+ libraries; (2) statistically significant (p<0.05) 
difference between human MYOEP and EPI groups based on t-test or Wilcox test (for rows A and B), or ratio 
of DMYOEP/NMYOEP > 10-fold (for row C); (3) ratio of ITGB6+/MUC1+ and MYOEP/EPI are in the same 
direction; (4) ratio of both ITGB6+/MUC1+ and MYOEP/EPI are ≥ 2-fold; and (5) tag count ≥10 in at least one 
of the primary human tissue libraries. Normalized tag counts, Unigene ID, gene symbol, gene description, and 
cellular localization (LOC) are listed. Abbreviation: N-normal, D-ductal carcinoma in situ, I-invasive ductal 
carcinoma, PM-plasma membrane, EC-extracellular, IC-intracellular, and NU-nuclear. Genes related to TGFβ1 
signaling are highlighted in yellow. Rows “A” and “B” denote genes high in ITGB6+ and MYOEP and MUC1+ 
and EPI cells, respectively, and row “C” represents genes high in ITGB6+ and D-MYOEP cells. 
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SUPPLEMENTAL DATA 
 
Supplemental Table 1. List of antibodies used. Antigen, antibody clone name, source, catalogue 
number (cat#), species, and application are listed. Abbreviations: FACS - Fluorescence-activated cell 
sorting, IB-Immunoblot, ICC-Immunocytochemistry, IHC-Immunohistochemistry, I-FISH-
Immunofluorescence combined with fluorescence in situ hybridization (FISH). Secondary antibodies 
were purchased from PIERCE (Rockford, IL) or Jackson ImmunoResearch Laboratories (West Grove, 
PA) 
 
Cluster analysis of SAGE libraries 
Differentially expressed tags (P < 0.05) between ITGB6+ and MUC1+ SAGE libraries from MCFDCIS 
xenografts were generated by Poisson analysis (available at http://genome.dfci.harvard.edu/sager/) (Cai et 
al., 2004).  Normalized tag counts per 50,000 from these two libraries were combined with those from 
human breast epithelial and myoepithelial libraries (N-EPI-1, N-EPI-2, N-MYOEP-1, N-MYOEP-2, N-
MYOEP-4, D-EPI-2, D-EPI-3, D-EPI-6, D-EPI-7, D-MYOEP-6, D-MYOEP-7. Tags were further filtered 
to have a maximum count from all libraries above 10 per 50,000 and to have a >1.5 fold difference 
between ITGB6 and MUC1 libraries.  Filtered data were log transformed and clustered (hierarchical, 
complete linkage) using the Cluster and TreeView software (Eisen et al., 1998). Color settings were 
adjusted to set tag count 4 per 50,000 as black.  Tag counts below 4 were green and above 4 were red. 
Antigen Clone name Source Cat # Species Application
CD10 56C6 Ventana Medical Systems, Inc 790-2923 mouse IHC
CD10-RPE SS2/36 DAKO R0848 mouse FACS
CD24 ML5 BD Biosciences 555426 mouse IHC
CD24-FITC ML5 BD Biosciences 555427 mouse FACS
CD44 515 BD Biosciences 550988 mouse IHC
CD44 156-3C11 NeoMarkers MS-668-P1 mouse IHC
CD44-PE G44-26 BD Biosciences 555479 mouse FACS
CD49f-PE GoH3 BD Biosciences 555736 rat FACS
Cox2 Cayman Chemical 160126 rabbit IHC
Cox2 CX229 Cayman Chemical 160112 mouse IHC
Cytokeratin 14 LL002 Novocastra Laboratories NCL-L-LL002 mouse IHC, ICC, IB
Cytokeratin 17 E3 DAKO M7046 mouse IHC
Cytokeratin 18 C51 Novocastra Laboratories NCL-C51 mouse IHC
Cytokeratin 19 RCK108 DAKO M0888 mouse IHC
Cytokeratin 5/6 D5/16 B4 DAKO M7237 mouse IHC
E-Cadherin 36 BD Biosciences 610181 mouse IHC
ESA B302 (323/A3) Biomeda V7018 mouse IHC
ESA-FITC B29.1 (VU-ID9) Biomeda FM010 mouse FACS
Integrin !6 6.2A1 Dr. Shelia Violette (Biogen Idec, Inc., Cambridge, MA) mouse IHC, IB
Integrin !6 6.3G9 Dr. Shelia Violette (Biogen Idec, Inc., Cambridge, MA) mouse FACS, purification
Integrin !6 ch2A1 Dr. Shelia Violette (Biogen Idec, Inc., Cambridge, MA) human IHC
Ki-67 antigen MIB1 DAKO M7240 mouse IHC
Ki-67 antigen Vector Laboratories VP-K451 rabbit IHC
Laminin 5 9LN5 Dr. William Brunken (Tufts University, Boston, MA) rabbit IHC, IB
Muc1 CT2 Dr. Donald Kufe (Dana Farber Cancer Institute, Boston, MA) hamster IB
Muc1 DF3 Dr. Donald Kufe (Dana Farber Cancer Institute, Boston, MA) mouse IHC, FACS, purification
p63 4A4 Calbiochem OP132 mouse IHC, IB
p63 4A4 Chemicon MAB4135 mouse IHC
Pan Cytokeratin AE1/AE3 DAKO M3515 mouse IHC, I-FISH
Smooth muscle actin 1A4 DAKO M0851 mouse IHC, I-FISH
Vimentin V9 DAKO M0725 mouse IHC, IB
beta-actin AC-74 Sigma A2228 mouse IB
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Supplemental Figure 1. Characterization of xenografts derived from invasive breast cancer cell 
lines. Histological and immunohistochemical analyses of the indicated xenografts derived from cell lines 
injected alone (-) or co-injected with normal myoepithelial cells (+HME). No DCIS histology and 
myoepithelial cell layer was detected in any of these tumors. SMA (smooth muscle actin) positive cells 
are mouse myofibroblasts and endothelial cells.  
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Supplemental Figure 2. Confirming the human origin of cytokeratin positive cells in MCFDCIS 
xenografts. Immuno-FISH analysis of the time course experiment demonstrates that cytokeratin (CTK) 
positive cells (blue cytoplasm) are of human origin. 
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Supplemental Figure 3. Analysis of MCFDCIS cell heterogeneity. A: FACS analysis of cultured cells 
for the indicated cell surface markers. With the exception of MUC1 the cells are homogenously positive 
(ITGA6, ESA, ITGB6, and CD44) or negative (CD10 and CD24) for the proteins analyzed. The 
expression of ITGB6 is further increased following TGFβ1 treatment. B: FACS sorting for MUC1+ and 
MUC1- cells and histology of xenografts resulting from them.  
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Supplemental Figure 4. Analysis of genetic changes in MCF10A series cells and MCFDCIS derived 
xenografts. A: SNP array analysis of the indicated cells and xenografts for copy number changes. Copy 
number gain of 8q24, including MYC, and homozygous deletion of CDKN2A at 9p21 are indicated. B: 
FISH confirmation of 8q24 copy number gain and insertion to 10q22. Left: MYC probe (red) gave three 
hybridization signals, two on chromosome 8 (green) and one on chromosome 10 (aqua). Right: MYC 
break apart probe (5’ red and 3’ green) shows two intact copies (yellow fused signal including both 5’ and 
3’ portions) on chromosome 8 (aqua) while the signal on chromosome 10 contains only the 5’ portion of 
the probe (red). C: SNP array analysis of the indicated cells and xenografts. An inferred LOH map 
including all chromosomes indicates that, with the exception of two tumors, all samples are genetically 
identical to the MCFDCIS cells. Blue and yellow colors indicate LOH and retention of both alleles, 
respectively.  
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Supplemental Excel Spreadsheet 1. Comparison of SAGE tags that are statistically significantly 
differentially expressed between ITGB6+ and MUC1+ cells to SAGE libraries prepared from 
human breast myoepithelial and epithelial cells. All SAGE libraries were normalized to total tag count 
of 100,000. Tags only present in ITGB6+ or MUC1+ cells from MCFDCIS xenografts and in none of the 
libraries prepared from primary human tissue were removed. Tags statistically significantly differentially 
(p<0.05) expressed between ITGB6+ and Muc1+ cells were linked to “MYOEP” (CD10+ myoepithelial 
cells purified from normal breast tissue or DCIS) and “EPI” (BerEP4+ epithelial cells purified from 
normal or cancerous breast tissue) samples. Two-tailed Student’s t-test (T-test) and Wilcox Rank Sum test 
(Wilcox test) were performed between the “MYOEP” and “EPI” groups, and the ratio of the mean of 
“MYOEP” and “EPI” groups was calculated (Ratio MYOEP/EPI). If the ratio of ITGB6+/MUC1+ and 
MYOEP/EPI are in the same and opposite directions then the tag is labeled as “+” and “-“, respectively 
(Direction). To select for DMYOEP specific genes, the ratio of the mean of “DMYOEP” and 
“NMYOEP” groups was also calculated (Ratio D/N). Tag sequence, normalized tag counts, p value for 
the difference between ITGB6+ and MUC1+ libraries, T-test, Wilcox test, Mean MYOEP, Mean EPI, 
Ratio MYOEP/EPI, Direction, Mean DMYOEP, MEAN NMYOEP, Ratio D/N, UniGene ID, Gene 
symbol, Gene description, and Cellular localization are listed. In the SAGE library names N-normal, D-
DCIS, and I-invasive ductal carcinoma. 
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